Pediatrix Medical Group (NYSE:MD) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen cut shares of Pediatrix Medical Group (NYSE:MD) from a strong-buy rating to a buy rating in a research note released on Saturday.

Several other analysts have also commented on MD. Leerink Partners lifted their price objective on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a “market perform” rating in a research report on Friday, September 5th. Zacks Research raised shares of Pediatrix Medical Group to a “strong-buy” rating in a report on Monday, August 11th. Finally, UBS Group upped their price objective on Pediatrix Medical Group from $16.00 to $16.50 and gave the company a “neutral” rating in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.79.

Pediatrix Medical Group Stock Down 0.5%

Shares of NYSE:MD opened at $16.56 on Friday. The company has a market capitalization of $1.44 billion, a PE ratio of 12.83 and a beta of 1.29. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80. The business has a fifty day moving average price of $14.81 and a two-hundred day moving average price of $14.18. Pediatrix Medical Group has a 1 year low of $10.39 and a 1 year high of $17.67.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.11. The company had revenue of $468.84 million for the quarter, compared to analysts’ expectations of $464.37 million. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The business’s revenue for the quarter was down 7.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 EPS. Analysts forecast that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Nuveen LLC purchased a new stake in shares of Pediatrix Medical Group during the first quarter worth $8,024,000. Ameriprise Financial Inc. raised its stake in shares of Pediatrix Medical Group by 175.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after purchasing an additional 474,186 shares during the period. American Century Companies Inc. lifted its holdings in Pediatrix Medical Group by 28.6% during the 2nd quarter. American Century Companies Inc. now owns 1,931,867 shares of the company’s stock worth $27,722,000 after purchasing an additional 430,029 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Pediatrix Medical Group by 669.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock worth $6,832,000 after purchasing an additional 414,216 shares in the last quarter. Finally, Hillsdale Investment Management Inc. boosted its stake in Pediatrix Medical Group by 75,200.0% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 376,500 shares of the company’s stock worth $5,403,000 after purchasing an additional 376,000 shares during the period. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.